Safety and efficacy of oxycodone for refractory dyspnea in end-stage heart failure patients with chronic kidney disease: a case series of eight patients
This study revealed the clinical practice of oxycodone treatment and suggested that it is an alternative therapy as a viable palliative for refractory dyspnea in patients with end-stage heart failure who should avoid the use of morphine.
Authors
- H. Ozaki
- Kazuichi Okazaki (ORCID: https://orcid.org/0000-0003-3424-3142)
- Kazuki Uchitani
- Hirofumi Maeba
- Takeshi Senoo
- Noboru Tanigawa (ORCID: https://orcid.org/0000-0002-7283-3381)
- Masayuki Tanaka
- Nana Yoshimiya
Institutions
- Setsunan University (JP)
- Kansai Medical University (JP)
- Mito Saiseikai General Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1186/s40780-024-00384-4
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00